For US Healthcare Professionals
I am a
Rheumatology Specialist
For US Healthcare Professionals
Full Prescribing Information
active PsA patients continued therapy on TREMFYA® in DISCOVER 2 through 2 years (Week 100) and in DISCOVER 1 prior to Week 481*
DISCOVER 2: Study disposition at Week 24 and through Week 100
DISCOVER 1: Study disposition at Week 24 and prior to Week 48
No conclusions regarding clinical efficacy or safety can be drawn.
*Year 2 represents Week 100.
†Discontinuations shown for patients who were randomized and received at least 1 study drug administration.
‡248 patients in DISCOVER 2 were randomized to the TREMFYA® 100 mg q4w dosing regimen through Week 112; TREMFYA® q4w was not an FDA-approved dosing regimen.
§1 patient-initiated, protocol-prohibited medication in the placebo group through Week 24.
Reference: 1. Data on file. Janssen Biotech, Inc.
Explore TREMFYA® safety data in clinical trials
Have a discussion with a Janssen representative
Talk with a Janssen representative
